Cystic fibrosis from laboratory to bedside: The role of a20 in NF-κB-mediated inflammation

Medical Principles and Practice

Volumn 24, Issue 4, 2015, Pages 301-310

  Bannon, Aidan ^a   Zhang, Shu Dong ^a   Schock, Bettina C ^a   Ennis, Madeleine ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

A20; Anti inflammatory effects; Cystic fibrosis; Drug repositioning; Gene connectivity mapping; Nuclear factor B

Indexed keywords

A20 PROTEIN; ANTIINFLAMMATORY AGENT; CYTOKINE; CYTOPLASM PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG; AUTACOID; DNA BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TAX1BP1 PROTEIN, HUMAN; TNF PROTEIN, HUMAN; TNFAIP3 PROTEIN, HUMAN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR PROTEIN;

ANTIINFLAMMATORY ACTIVITY; CHRONIC AIRWAY INFLAMMATION; CYSTIC FIBROSIS; CYTOKINE RELEASE; DRUG REPOSITIONING; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LABORATORY TEST; LUNG FUNCTION; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; REVIEW; SURVIVAL RATE; BIOSYNTHESIS; CELL CULTURE TECHNIQUE; CHROMOSOMAL MAPPING; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION;

CELL CULTURE TECHNIQUES; CHROMOSOME MAPPING; CYSTIC FIBROSIS; CYTOKINES; DNA-BINDING PROTEINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; NF-KAPPA B; NUCLEAR PROTEINS; PHENOTYPE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934441434     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000381423     Document Type: Review

References (88)

1. Rowe SM, Miller S, Sorscher EJ: Cystic fibro-sis. N Engl J Med 2005; 352:1992-2001.
2. Lange T, Jungmann P, Haberle J, et al: Reduced number of CFTR molecules in erythro-cyte plasma membrane of cystic fibrosis patients. Mol Membr Biol 2006; 23:317-323.
3. O'Sullivan BP, Freedman SD: Cystic fibrosis. Lancet 2009; 373:1891-1904.
4. Frossard PM, Lestringant G, Girodon E, et al: Determination of the prevalence of cystic fi-brosis in the United Arab Emirates by genetic carrier screening. Clin Genet 1999; 55:496-497.
5. Mathew PM, Hamdan JA, Nazer H: Cystic fi-brosis presenting with recurrent vomiting and metabolic alkalosis. Eur J Pediatr 1991; 150:264-266.
6. Ratjen F, Doring G: Cystic fibrosis. Lancet 2003; 361:681-689.
7. Dodge JA, Lewis PA, Stanton M, et al: Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007; 29:522-526.
8. Lao O, Andres AM, Mateu E, et al: Spatial patterns of cystic fibrosis mutation spectra in European populations. Eur J Hum Genet 2003; 11: 385-394.
9. Walters S, Mehta A: Epidemiology of cystic fibrosis; in Hodson M, Geddes DM, Bush A (eds): Cystic Fibrosis, ed 3. Boca Raton, CRC Press, 2007, pp 21-45.
10. Jennings MT, Riekert KA, Boyle MP: Updates on key emerging challenges in cystic fibrosis. Med Princ Pract 2014; 23:393-402.
11. Anderson DH: Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 1938; 56:344.
12. Wilschanski M, Durie PR: Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56:1153-1163.
13. Cystic Fibrosis Foundation Patient Registry: 2006 Annual Data Report to the Center Directors. Bethedsa, Cystic Fibrosis Foundation, 2007.
14. Matsui H, Grubb BR, Tarran R, et al: Evidence for perciliary liquid layer depletion, not abnormal ion composition in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95: 1005-1115.
15. Matsui H, Wagner VE, Hill DB, et al: A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aerugino-sa biofilms. Proc Natl Acad Sci USA 2006; 103: 18131-18136.
16. Boucher RC: Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007; 58:157-170.
17. Tomashefski JF, Abramowsky CR, Dahms BB: The pathology of cystic fibrosis; in Davis PB (ed): Cystic Fibrosis. New York, Dekker, 1993, pp 435-489.
18. Khan TZ, Wagener JS, Bost T, et al: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
19. McGarvey LP, Dunbar K, Martin SL, et al: Cy-tokine concentrations and neutrophil elastase activity in bronchoalveolar lavage and induced sputum from patients with cystic fibro-sis, mild asthma and healthy volunteers. J Cyst Fibros 2002; 1:269-275.
20. De Boer K, Vandemheen KL, Tullis E, et al: Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011; 66:680-685.
21. Chmiel JF, Berger M, Konstan MW: The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23:5-27.
22. Cystic Fibrosis Registry: Cystic Fibrosis Our Focus. Annual Data Report, 2013. Bromley, Cystic Fibrosis Trust, 2014.
23. Szaff M, Hoiby N, Flensborg EW: Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983; 72:651-657.
24. Regelmann WE, Elliot GR, Warwick WJ, et al: Reduction of sputum Pseudomonas aerugino-sa density by antibiotics improves lung function in cystic fibrosis more than bronchodila-tors and chest physiotherapy alone. Am Rev Respir Dis 1990; 141:914-921.
25. Sadikot RT, Zeng H, Joo M, et al: Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa. J Immunol 2006; 176:4923-4930.
26. Kelly C, Canning P, Buchanan PJ, et al: Tolllike receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2013; 304:371-378.
27. Greene CM, Carroll TP, Smith SG, et al: TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol 2005; 174:1638-1646.
28. Hauber HP, Tulic MK, Tsicopoulos A, et al: Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cystic fi-brosis. Can Respir J 2005; 12:13-18.
29. John G, Yildirim AO, Rubin BK, et al: TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells. Am J Respir Cell Mol Biol 2010; 42:424-431.
30. Schroeder TH, Lee MM, Yacono PW, et al: CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci USA 2002; 99:6907-6912.
31. Jacquot J, Tabary O, Le Rouzic P, et al: Airway epithelial cell inflammatory signalling in cystic fibrosis. Int J Biochem Cell Biol 2008; 40: 1703-1715.
32. Imundo L, Barasch J, Prince A, et al: Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 1995; 92:3019-3023.
33. Campodonico VL, Gadjeva M, Paradis-Bleau C, et al: Airway epithelial control of Pseudo-monas aeruginosa infection in cystic fibrosis. Trends Mol Med 2008; 14:120-133.
34. Gruenert DC, Willems M, Cassiman JJ, et al: Established cell lines used in cystic fibrosis research. J Cyst Fibros 2004; 3:191-196.
35. Becker MN, Sauer MS, Muhlebach MS, et al: Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med 2004; 169:645-653.
36. Carrabino S, Carpani D, Livraghi A, et al: Dysregulated interleukin-8 secretion and NF-kappaB activity in human cystic fibrosis nasal epithelial cells. J Cyst Fibros 2006; 5:113-119.
37. De Courcey F, Zholos AV, Atherton-Watson H, et al: Development of primary human nasal epithelial cell cultures for the study of cystic fibrosis pathophysiology. Am J Physiol Cell Physiol 2012; 303:1173-1179.
38. Stott JB, de Courcey F, Ennis M, et al: Functional and pharmacological characterization of volume-regulated anion channels in human normal and cystic fibrosis bronchial and nasal epithelial cells. Eur J Pharmacol 2014; 740:183-191.
39. Kelly C, Williams MT, Mitchell K, et al: Expression of the nuclear factor-κB inhibitor A20 is altered in the cystic fibrosis epithelium. Eur Respir J 2013; 41:1315-1323.
40. Kelly C, Shields MD, Elborn JS, et al: A20 regulation of nuclear factor-κB: perspectives for inflammatory lung disease. Am J Respir Cell Mol Biol 2011; 44:743-748.
41. Shembade N, Ma A, Harhaj EW: Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010; 327:1135-1139.
42. Vereecke L, Beyaert R, van Loo G: The ubiq-uitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009; 30:383-391.
43. Zaman MM, Gelrud A, Junaidi O, et al: Inter-leukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin Diagn Lab Immunol 2004; 11:819-824.
44. Colombo C, Costantini D, Rocchi A, et al: Cy-tokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pe-diatr Pulmonol 2005; 40:15-21.
45. Karp CL, Flick LM, Park KW, et al: Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5:388-392.
46. Bonfield TL, Konstan MW, Berger M: Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104:72-78.
47. Yang Z, Klionsky DJ: An overview of the molecular mechanism of autophagy. Curr Top Microbiol Immunol 2009; 335:1-32.
48. Trocoli A, Djavaheri-Mergny M: The complex interplay between autophagy and NF-κB signaling pathways in cancer cells. Am J Cancer Res 2011; 1:629-649.
49. Schmid D, Münz C: Innate and adaptive immunity through autophagy. Immunity 2007; 27:11-21.
50. Luciani A, Villella VR, Esposito S, et al: Cystic fibrosis: a disorder with defective autophagy. Autophagy 2011; 104-106.
51. Junkins RD, McCormick C, Lin T-J: The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections. Autophagy 2014; 538-547.
52. Abdulrahman BA, Khweek AA, Akhter A, et al: Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy 2011; 7:1359-1370.
53. Opipari AW Jr, Boguski MS, Dixit VM: The A20 cDNA induced by tumour necrosis factor α encodes a novel type of zinc finger protein. J Biol Chem 1990; 265:14705-14708.
54. Blackwell TS, Stecenko AA, Christman JW: Dysregulated NF-kappaB activation in cystic fibrosis: evidence for a primary inflammatory disorder. Am J Physiol Lung Cell Mol Physiol 2001; 281:69-70.
55. Da Silva CG, Studer P, Skroch M, et al: A20 promotes liver regeneration by decreasing SOCS3 expression to enhance IL-6/STAT3 proliferative signals. Hepatology 2013; 57: 2014-2025.
56. Mabilleau G, Chappard D, Sabokbar A: Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis. J Biol Chem 2011; 286:3242-3249.
57. Shembade N, Parvatiyar K, Harhaj NS, et al: The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J 2009; 28:513-522.
58. Shembade N, Pujari R, Harhaj NS, et al: The kinase IKKα inhibits activation of the transcription factor NF-κB by phosphorylating the regulatory molecule TAX1BP1. Nat Immunol 2011; 12:834-843.
59. Wertz IE, O'Rourke KM, Zhou H, et al: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430:694-699.
60. De A, Dainichi T, Rathinam CV, et al: The deubiquitinase activity of A20 is dispensable for NF-κB signaling. EMBO Rep 2014; 15: 775-783.
61. Opipari AW Jr, Hu HM, Yabkowitz R, et al: The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992; 267:12424-12427.
62. Barmada MM, Brant SR, Nicolae DL, et al: A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 2004; 10:513-520.
63. Vereecke L, Sze M, Guire CM, et al: Entero-cyte specific A20 deficiency sensitizes to tumour necrosis factor-induced toxicity and experimental colitis. J Exp Med 2010; 207:1513-1523.
64. Onose A, Hashimoto S, Hayashi S, et al: An inhibitory effect of A20 on NF-kappaB activation in airway epithelium upon influenza virus infection. Eur J Pharmacol 2006; 541:198-204.
65. Tiesset H, Pierre M, Desseyn JL, et al: Dietary (n-3) polyunsaturated fatty acids affect the kinetics of pro-and anti-inflammatory responses in mice with Pseudomonas aerugino-sa lung infection. J Nutr 2009; 139:82-89.
66. Gon Y, Asai Y, Hashimoto S, et al: A20 inhibits toll-like receptor 2-and 4-mediated inter-leukin-8 synthesis in airway epithelial cells. Am J Respir Cell Mol Biol 2004; 31:330-336.
67. Sisto M, Lisi S, Lofrumento DD, et al: A failure of TNFAIP3 negative regulation maintains sustained NF-kappaB activation in Sjorgen's syndrome. Histochem Cell Biol 2011; 135: 615-625.
68. Kelly C, Williams MT, Elborn JS, et al: Expression of the inflammatory regulator A20 correlates with lung function in patients with cystic fibrosis. J Cyst Fibros 2013; 12:411-415.
69. Collett GP, Campbell FC: Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2006; 27:1285-1291.
70. Hedden P: Plant biology: gibberellins close the lid. Nature 2008; 456:455-456.
71. Holden NS, Rider CF, Bell MJ, et al: Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action. Br J Pharmacol 2010; 160:410-420.
72. Davis RH, Maro NP: Aloe vera and gibberel-lin. Anti-inflammatory activity in diabetes. J Am Podiatr Med Assoc 1989; 79:24-26.
73. Jenkins PJ: Preparation and diabetic use of gibberellins. US patent No 0796859602 A1, 2006.
74. Oden P: The use of gibberellins for the treatment of prostatitis and psoriasis. European Patent No 0504254 A1, 1990.
75. Reihill J, Malcomson B, Barsden R, et al: Defective A20 signalling in cystic fibrosis: an anti-inflammatory action of gibberellin (abstract). J Cyst Fibros 2014; 13:574.
76. Kang NI, Yoon HY, Lee YR, et al: A20 attenuates allergic airway inflammation in mice. J Immunol 2009; 183:1488-1495.
77. Tan Y, Liu H, Yang H, et al: An inactivated Pseudomonas aeruginosa medicament inhibits airway allergic inflammation and improves epithelial functions. J Physiol Sci 2013; 63: 63-69.
78. Mestre-Ferrandiz J, Sussex J, Towse A: The R&D Cost of a New Medicine. London, Office of Health Economics UK, 2012.
79. Paul SM, Mytelka DS, Dunwiddie CT, et al: How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010; 9:203-214.
80. Dickson M, Gagnon JP: Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 2004; 3:417-429.
81. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22:151-185.
82. Blume C, Davies DE: In vitro and ex vivo models of human asthma. Eur J Pharm Bio-pharm 2013; 84:394-400.
83. Holmes AM, Solari R, Holgate ST: Animal models of asthma: value, limitations and opportunities for alternative approaches. Drug Discov Today 2011; 16:659-670.
84. Ashburn TT, Thor KB: Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3:673-683.
85. McArt DG, Zhang SD: Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. PLoS One 2011; 6:e16382.
86. Zhang SD, Gant TW: A simple and robust method for connecting small-molecule drugs using gene-expression signatures. BMC Bio-informatics 2008; 9:258.
87. Ramsey JM, Kettyle LM, Sharpe DJ, et al: En-tinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia. Stem Cells 2013; 31:1434-1445.
88. Barsden R, Elborn JS, Schock BC, et al: Connectivity mapping: an advanced approach to predict A20 inducing small molecules to reduce inflammation (abstract). J Cyst Fibros 2014; 13:574.